Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05349383
Other study ID # CSU20220499
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 22, 2022
Est. completion date June 1, 2022

Study information

Verified date June 2022
Source Central South University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Although antibody-drug conjugate(ADC) has proved effective in treating many cancers, few patients receiving ADC may experience rare but life-threatening sepsis-related toxicities such as sepsis and septic shock. Today, data about sepsis/septic shock are scarce. The objective was to investigate reports of sepsis/septic shock adverse events related to ADC, including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin using international pharmacovigilance databases such as the FDA Adverse Event Reporting System (FAERS).


Description:

Here, investigators use international pharmacovigilance databases such as the FDA Adverse Event Reporting System (FAERS) of individual safety case reports, to identify cases of sepsis-related toxicities related to ADC.


Recruitment information / eligibility

Status Completed
Enrollment 24618
Est. completion date June 1, 2022
Est. primary completion date May 22, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: Case reported in the FDA Adverse Event Reporting System (FAERS) or other international pharmacovigilance database of individual safety case reports to 12/31/2022 Adverse event reported were included the report with MedDRA terms: Sepsis(SMQ), agranulocytosis(SMQ), Opportunistic infections (SMQ). Patients treated with ADC included: Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin. Other cancer patients received common drug therapies such as chemotherapy, targeted therapy or immunotherapy would also be included as a comparator. Exclusion Criteria: Chronology not compatible between ADC and adverse event (sepsis-related toxicities)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Antibody-Drug Conjugate
Compared the case reporting of sepsis-related toxicities among ADC and other common cancer drug therapies. ADC:including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin.
Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
We would like to include other common cancer drug therapies such as chemotherapy, targeted therapy, immunotherapy and so on as a comparator group.

Locations

Country Name City State
China Central South University Changsha Hunan

Sponsors (1)

Lead Sponsor Collaborator
Central South University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sepsis-related toxicity of antibody-drug conjugate. Identification and report of the sepsis-related toxicity of ADC. The research includes the report with MedDRA terms: Sepsis(SMQ), agranulocytosis(SMQ), Opportunistic infections (SMQ). Drugs investigated are ADC: Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin. Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022
Secondary Causality assessment of reported cardiovascular events according to the WHO system Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022
Secondary Description of the type of sepsis-related toxicities depending on the category of ADC Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022
Secondary Description of the drug-drug interactions associated with sepsis-related adverse events Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022
Secondary Description of the population of patients having a sepsis-related adverse events Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022
Secondary Description of the pathologies (cancer) for which the incriminated drugs have been prescribed Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022
See also
  Status Clinical Trial Phase
Recruiting NCT02454569 - Vicente Ferrer HIV Cohort Study
Completed NCT02942173 - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT Phase 2/Phase 3
Recruiting NCT02982902 - T Cell Therapy of Opportunistic Cytomegalovirus Infection Early Phase 1
Not yet recruiting NCT01541631 - A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes N/A
Completed NCT03087890 - Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria Phase 4
Active, not recruiting NCT00814827 - Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma
Completed NCT01557803 - Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome N/A
Recruiting NCT03798301 - Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells Phase 1
Completed NCT00137657 - Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance Phase 4
Active, not recruiting NCT05694546 - Re-engagement at Discharge 2 N/A
Recruiting NCT02337595 - Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT03083756 - Validation of a Risk Score Opportunistic Infections Development in Kidney Transplant Patients N/A
Completed NCT00001477 - Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy N/A